Emerging medicinal roles for lysophospholipid signaling

Trends in Molecular Medicine

Volumn 12, Issue 2, 2006, Pages 65-75

  Gardell, Shannon E ^a   Dubin, Adrienne E ^a   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; ANTINEOPLASTIC AGENT; CYCLOSPORIN; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; IMMUNOSUPPRESSIVE AGENT; KI 16425; LIPOPROTEIN A; LYSOPHOSPHOLIPID; NEUROTRANSMITTER; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CANCER; CARDIOVASCULAR DISEASE; CELL AGGREGATION; CELL DAMAGE; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG POTENTIATION; DRUG TARGETING; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIPID METABOLISM; LIPOGENESIS; MENTAL DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; TUMOR CELL;

ANIMALS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASMS; OBESITY; PHOSPHORYLATION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE; TRANSPLANTATION IMMUNOLOGY;

ANIMALIA;

EID: 32044448106     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.12.001     Document Type: Review

References (120)

1. A. Wise Target validation of G-protein coupled receptors Drug Discov. Today 7 2002 235 246
2. I. Ishii Lysophospholipid receptors: signaling and biology Annu. Rev. Biochem. 73 2004 321 354
3. B. Anliker, and J. Chun Lysophospholipid G protein-coupled receptors J. Biol. Chem. 279 2004 20555 20558
4. A.M. Manning, and R.J. Davis Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2 2003 554 565
5. M. McDermott Phospholipase D Biochem. Cell Biol. 82 2004 225 253
6. B.K. Mueller Rho kinase, a promising drug target for neurological disorders Nat. Rev. Drug Discov. 4 2005 387 398
7. H. Liu Sphingosine kinases: a novel family of lipid kinases Prog. Nucleic Acid Res. Mol. Biol. 71 2002 493 511
8. R.I. Lechler Organ transplantation - how much of the promise has been realized? Nat. Med. 11 2005 605 613
9. T. Fujita Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite J. Antibiot. (Tokyo) 47 1994 208 215
10. V. Brinkmann The immune modulator FTY720 targets sphingosine 1-phosphate receptors J. Biol. Chem. 277 2002 21453 21457
11. S. Mandala Alteration of lymphocyte trafficking by sphingosine-1- phosphate receptor agonists Science 296 2002 346 349
12. Wei, S.H. et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat. Immunol. (in press)
13. G. Cinamon Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone Nat. Immunol. 5 2004 713 720
14. M. Matloubian Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 2004 355 360
15. 1, on T-cells controls thymic emigration J. Biol. Chem. 279 2004 15396 15401
16. M.H. Graler, and E.J. Goetzl The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors FASEB J. 18 2004 551 553
17. D.D. Pinschewer FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory J. Immunol. 164 2000 5761 5770
18. 3, respectively, regulate lymphocyte recirculation and heart rate J. Biol. Chem. 279 2004 13839 13848
19. V. Brinkmann, and K.R. Lynch FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity Curr. Opin. Immunol. 14 2002 569 575
20. M. Fujino Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment J. Pharmacol. Exp. Ther. 305 2003 70 77
21. M. Webb Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice J. Neuroimmunol. 153 2004 108 121
22. A. Cifelli Thalamic neurodegeneration in multiple sclerosis Ann. Neurol. 52 2002 650 653
23. T. Levade Sphingolipid mediators in cardiovascular cell biology and pathology Circ. Res. 89 2001 957 968
24. N. Osborne, and D.Y. Stainier Lipid receptors in cardiovascular development Annu. Rev. Physiol. 65 2003 23 43
25. Y. Liu Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation J. Clin. Invest. 106 2000 951 961
26. 1 acts within endothelial cells to regulate vascular maturation Blood 102 2003 3665 3667
27. 3 function coordinately during embryonic angiogenesis J. Biol. Chem. 279 2004 29367 29373
28. J.J. Maguire, and A.P. Davenport Regulation of vascular reactivity by established and emerging GPCRs Trends Pharmacol. Sci. 26 2005 448 454
29. W. Siess Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate Biochim. Biophys. Acta 1582 2002 204 215
30. E. Rother Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques Circulation 108 2003 741 747
31. M.J. Kluk, and T. Hla Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration Circ. Res. 89 2001 496 502
32. D. Zohlnhofer Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein 12 upregulation Circulation 103 2001 1396 1402
33. F. Coussin Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction Circ. Res. 91 2002 151 157
34. 3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate Eur. J. Pharmacol. 469 2003 125 134
35. 3 Circ. Res. 96 2005 913 920
36. 2 Cardiovasc. Res. 58 2003 170 177
37. 3 J. Clin. Invest. 113 2004 569 581
38. E. Sawicka Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720 J. Immunol. 171 2003 6206 6214
39. B. McVerry, and J. Garcia In vitro and in vivo modulation of vascular barrier integrity by sphingosine1-phosphate: mechanistic insights Cell. Signal. 17 2005 131 139
40. K. Konishi Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model J. Heart Lung Transplant. 21 2002 692 700
41. P.S. Jolly The roles of sphingosine-1-phosphate in asthma Mol. Immunol. 38 2002 1239 1245
42. A.J. Ammit Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma FASEB J. 15 2001 1212 1214
43. S. Spiegel, and R. Kolesnick Sphingosine 1-phosphate as a therapeutic agent Leukemia 16 2002 1596 1602
44. J.G. Garcia Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement J. Clin. Invest. 108 2001 689 701
45. 3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF Proc. Natl. Acad. Sci. U. S. A. 102 2005 9270 9275
46. H. Azuma Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models Cancer Res. 62 2002 1410 1419
47. T.K. Lee FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation Carcinogenesis 25 2004 2397 2405
48. M. Yang G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway Proc. Natl. Acad. Sci. U. S. A. 102 2005 6027 6032
49. P. Xia An oncogenic role of sphingosine kinase Curr. Biol. 10 2000 1527 1530
50. K.J. French Discovery and evaluation of inhibitors of human sphingosine kinase Cancer Res. 63 2003 5962 5969
51. G.B. Mills, and W.H. Moolenaar The emerging role of lysophosphatidic acid in cancer Nat. Rev. Cancer 3 2003 582 591
52. A. Tokumura Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase J. Biol. Chem. 277 2002 39436 39442
53. M. Umezu-Goto Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J. Cell Biol. 158 2002 227 233
54. S. Jansen Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D J. Cell Sci. 118 2005 3081 3089
55. S.W. Nam Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells Oncogene 19 2000 241 247
56. S.W. Nam Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor Cancer Res. 61 2001 6938 6944
57. T. Yamada Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1 J. Biol. Chem. 279 2004 6595 6605
58. D.L. Baker Plasma lysophosphatidic acid concentration and ovarian cancer J. Am. Med. Assoc. 287 2002 3081 3082
59. R. Sutphen Lysophospholipids are potential biomarkers of ovarian cancer Cancer Epidemiol. Biomarkers Prev. 13 2004 1185 1191
60. L.T. Budnik, and A.K. Mukhopadhyay Lysophosphatidic acid and its role in reproduction Biol. Reprod. 66 2002 859 865
61. M. Inoue Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling Nat. Med. 10 2004 712 718
62. K. Renback Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission Mol. Brain Res. 75 2000 350 354
63. K. Renback Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice Neurosci. Lett. 270 1999 59 61
64. S. Love Central demyelination of the Vth nerve root in trigeminal neuralgia associated with vascular compression Brain Pathol. 8 1998 1 11
65. R.M. Bilder Schizophrenia as a neurodevelopmental disorder Curr. Opin. Pyschiatry 14 2001 9 15
66. A.K. Das, and A.K. Hajra Quantification, characterization and fatty acid composition of lysophosphatidic acid in different rat tissues Lipids 24 1989 329 333
67. Y. Yatomi Distribution of sphingosine 1-phosphate, a bioactive sphingolipid, in rat tissues FEBS Lett. 404 1997 173 174
68. N. Fukushima Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology Dev. Biol. 228 2000 6 18
69. H. Kawagoe Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2) Genomics 30 1995 380 384
70. C. McGiffert Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis FEBS Lett. 531 2002 103 108
71. J.A. Weiner Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain J. Comp. Neurol. 398 1998 587 598
72. J.J. Contos, and J. Chun Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA Genomics 64 2000 155 169
73. M.A. Kingsbury Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding Nat. Neurosci. 6 2003 1292 1299
74. J.J. Contos Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior Proc. Natl. Acad. Sci. U. S. A. 97 2000 13384 13389
75. 2 Mol. Cell. Biol. 22 2002 6921 6929
76. S.M. Harrison LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease Mol. Cell. Neurosci. 24 2003 1170 1179
77. D.L. Braff Gating and habituation of the startle reflex in schizophrenic patients Arch. Gen. Psychiatry 49 1992 206 215
78. G. Corfas Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia Nat. Neurosci. 7 2004 575 580
79. Y. Hakak Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia Proc. Natl. Acad. Sci. U. S. A. 98 2001 4746 4751
80. J. Allard A rat G protein-coupled receptor selectively expressed in myelin-forming cells Eur. J. Neurosci. 10 1998 1045 1053
81. 3-mediated lysophosphatidic acid signalling in embryo implantation and spacing Nature 435 2005 104 108
82. A. Tokumura Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients Biol. Reprod. 61 1999 195 199
83. Y. Morita Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy Nat. Med. 6 2000 1109 1114
84. Y. Morita, and J.L. Tilly Sphingolipid regulation of female gonadal cell apoptosis Ann. N. Y. Acad. Sci. 905 2000 209 220
85. J.L. Tilly, and R.N. Kolesnick Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility Biochim. Biophys. Acta 1585 2002 135 138
86. W. Gogarten Oxytocin and lysophosphatidic acid induce stress fiber formation in human myometrial cells via a pathway involving Rho-kinase Biol. Reprod. 65 2001 401 406
87. A. Tokumura Stimulatory effect of lysophosphatidic acids on uterine smooth muscles of non-pregnant rats Arch. Int. Pharmacodyn. Ther. 245 1980 74 83
88. T.G. Kennedy Evidence for a role for prosaglandins in the initiation of blastocyst implantation in the rat Biol. Reprod. 16 1977 286 291
89. K. Kinoshita Involvement of prostaglandins in implantation in the pregnant mouse Adv. Prostaglandin Thromboxane Leukot. Res. 15 1985 605 607
90. K. Bandoh Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid J. Biol. Chem. 274 1999 27776 27785
91. E.R. Roldan Role of phospholipases during sperm acrosomal exocytosis Front. Biosci. 3 1998 D1109 D1119
92. J. Yue Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level Cell. Signal. 16 2004 385 399
93. G. Reaven Obesity, insulin resistance, and cardiovascular disease Recent Prog. Horm. Res. 59 2004 207 223
94. M. Lafontan Fat cells: afferent and efferent messages define new approaches to treat obesity Annu. Rev. Pharmacol. Toxicol. 45 2005 119 146
95. C. Pages Lysophosphatidic acid synthesis and release Prostaglandins Other Lipid Mediat. 64 2001 1 10
96. M.F. Simon Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor γ2 J. Biol. Chem. 280 2005 14656 14662
97. G. Ferry Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity J. Biol. Chem. 278 2003 18162 18169
98. T.M. McIntyre Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist Proc. Natl. Acad. Sci. U. S. A. 100 2003 131 136
99. 1 (EDG2) phospholipid growth factor receptors J. Biol. Chem. 276 2001 49213 49220
100. H. Ohta Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors Mol. Pharmacol. 64 2003 994 1005
101. M. Osada Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist Biochem. Biophys. Res. Commun. 299 2002 483 487
102. K. Budde First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients J. Am. Soc. Nephrol. 13 2002 1073 1083
103. A. Boucharaba Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer J. Clin. Invest. 114 2004 1714 1725
104. K. Inoue Chronic pain and microglia: the role of ATP Novartis Found. Symp. 261 2004 55 64
105. J. Radeff-Huang G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival J. Cell. Biochem. 92 2004 949 966
106. K. Hama Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1 J. Biol. Chem. 279 2004 17634 17639
107. E. Malchinkhuu Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1- phosphate in glioma cells Oncogene 24 2005 6676 6688
108. D. Bian Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway Cancer Res. 64 2004 4209 4217
109. T. Sanchez PTEN as an effector in the signaling of antimigratory G protein-coupled receptor Proc. Natl. Acad. Sci. U. S. A. 102 2005 4312 4317
110. Y.A. DeClerck Proteases, extracellular matrix, and cancer: a workshop of the path B study section Am. J. Pathol. 164 2004 1131 1139
111. H. Li Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells J. Biol. Chem. 280 2005 10564 10571
112. 2+ influx in human platelets J. Biol. Chem. 275 2000 19159 19166
113. K. Hayashi Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids Circ. Res. 89 2001 251 258
114. K.R. Watterson The role of sphingosine-1-phosphate in smooth muscle contraction Cell. Signal. 17 2005 289 298
115. J.A. Weiner, and J. Chun Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid Proc. Natl. Acad. Sci. U. S. A. 96 1999 5233 5238
116. Y. Li Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells J. Biol. Chem. 278 2003 9585 9591
117. T.J. Manning Jr Role of lysophosphatidic acid and rho in glioma cell motility Cell Motil. Cytoskeleton 45 2000 185 199
118. 2+-α-actinin and polymerization by rho Mol. Biol. Cell 13 2002 2692 2705
119. F.W. Holtsberg Lysophosphatidic acid induces a sustained elevation of neuronal intracellular calcium J. Neurochem. 69 1997 68 75
120. J.A. Weiner Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling J. Neurosci. 21 2001 7069 7078